Connect Biopharma/$CNTB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Connect Biopharma
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Ticker
$CNTB
Sector
Primary listing
Employees
64
Headquarters
Website
CNTB Metrics
BasicAdvanced
$133m
-
-$1.15
-
-
Price and volume
Market cap
$133m
52-week high
$3.82
52-week low
$1.23
Average daily volume
201k
Financial strength
Current ratio
3.228
Quick ratio
2.701
Long term debt to equity
0.673
Total debt to equity
1.626
Profitability
EBITDA (TTM)
-65.539
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-27,727.90%
Operating margin (TTM)
-28,426.61%
Effective tax rate (TTM)
-0.30%
Management effectiveness
Return on assets (TTM)
-54.20%
Return on equity (TTM)
-102.94%
Valuation
Price to revenue (TTM)
564.497
Price to book
3.46
Price to tangible book (TTM)
3.46
Price to free cash flow (TTM)
-2.283
Free cash flow yield (TTM)
-43.81%
Free cash flow per share (TTM)
-1.029
Growth
Revenue change (TTM)
-99.11%
Earnings per share change (TTM)
265.68%
3-year earnings per share growth (CAGR)
-15.18%
CNTB News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs